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ABSTRACT
Objective: To evaluate the management and survival of patients with advanced prostate
cancer in this locality.
Design: A prospective case study.
Setting: Kenyatta National Referral Hospital and the Nairobi and Mater Hospitals.
Patients: Fifty nine patients with advanced cancer of prostate (extra prostatic locally
advanced and metastatic cancer).
Results: Transperineal trucut needle biopsies of the prostate revealed 15 patients (25.42%)
had poorly differentiated cancers with Gleasons scores greater than 7. Fifteen patients
(25.42%) had moderately differentiated cancers with Gleason scores of 6; and twenty nine
other patients (49.2%) had well differentiated cancers with Gleason scores of 4 and below.
Surgical castration was effected on 15 patients four of whom also had 50 mg of oral
bicalutamide (casodex) daily. Thirty six patients were treated with subcutaneous goserelin
(zoladex) depot 3.6mg every 28 days. Ten of these patients also had 50 mg oral casodex daily
in addition to the zoladex. Three patients in this group also had external radiotherapy for
severe bone pains. Only eight patients were treated with oral diethylstilboestrol 3 mg daily.
All the 15 patients with undifferentiated cancers died within 12 months. Of the 22 patients
surviving at 48 months irrespective of the method of treatment, 20 of them had well
differentiated cancers with Gleasons scores of 4 or less.
Conclusion: Survival in the undifferentiated and poorly differentiated prostrate cancer
Gleasons grades 4 and 5 with a score of over 7 is poor irrespective of the mode of treatment
as all the patients in this group were dead within 12 months of diagnosis. Twenty patients
(90.90%) of the surviving patients at 48 months had well differentiated cancers Gleasons
grades 1 and 2 with scores of 4 or less indicating better prognosis for these tumours which
are known to be  slow growing with a much longer tumour doubling time.
INTRODUCTION
Prostate cancer is the most common male cancer and
the second leading cause of cancer death in American
men(1). The disease is also common in Europe and is the
third commonest cause of cancer death in the United
Kingdom(2,3). Prostate cancer has also been reported as
the most common genitourinary malignancy by African
authors(4-8). This is as a result of increased awareness of
the disease, increased life expectancy, improved diagnostic
techniques and screening procedures which include the
use of serum prostate specific antigen (PSA)(l,9). The
incidence of prostate cancer is thus increasing worldwide
both as a result of organised screening programmes in
some countries and an apparent increase in
incidence(10,11). Prostate cancer commonly occurs in
men above 50 years, with more than 80% of all cases being
diagnosed in men over 65 years of age, and less than one
per cent in men under 50 years of age. The median age at
diagnosis of prostate cancer is 72 years although active
screening programmes in some countries may ultimately
lead to lowering of the median age of first diagnosis.
The epidemiology of prostate cancer is complex with
only a few established risk factors. Those most established
are family history, age, race, country and testosterone
deficiency(12-14). In the United States of America, the
presentation of black Americans with more advanced
prostate cancer than white Americans has been attributed
in part to the differential use of the available medical
resources in that country(15). Only a small proportion of
men diagnosed with prostate cancer eventually die from
the disease. It has now been established by Stamey et
al(16) that a tumour volume of less than 0.5mls and a
Gleason score of less than 7 would not be life threatening
because such prostate cancer has a long doubling time.
Prostate needle biopsies which identify microfocal cancer
with a tumour volume of less than 3mls and a Gleason
score of less than 7 creates a management dilemma for
urologist(17).
Many prostate cancers are diagnosed at the stage of
bony metastases when treatment can best be palliative.
Current population screening techniques are at best
controversial(2). The sensitivity and specificity of PSA
levels, digital rectal examination (DRE) and transrectal
ultrasound of the prostate (TRUS) are low, and no screening
May 2000 EAST AFRICAN MEDICAL JOURNAL 261
test has been shown to reduce mortality in prostate cancer.
Furthermore, studies have shown that clinical staging of
prostate cancer frequently underestimates the pathological
stage of the tumour(18,19).
MATERIALS AND METHODS
This is a prospective study involving 59 patients with
advanced prostate cancer. All patients presented with urinary
outflow problems. Twenty nine patients (49.15%) in this group
first presented late with acute urinary retention. Digital rectal
examination (DRE) was performed on the left lateral position by
the same investigator. Transrectal ultrasound of the prostate was
performed on 49 (83.05%) patients. Transperineal trucut needle
biopsy of the prostate was performed under digital guide in all
patients. Blood was taken for serum prostate specific antigen
(PSA) in 50 patients (84.75%). Plain x-rays of the pelvis and
lumbosacral spine were taken in all patients. X-rays of the
thoracic spine and chest were taken in 20 patients (33.90%).
Intravenous urogram (IVU) was performed in 40 patients
(67.80%). Eight patients were treated with oral diethylstilboestrol
1mg three times daily. Fifteen patients (25.42%) had bilateral
orchidectomy. Thirty six patients (67.8%) were treated with
3.6mg subcutanous depot of zoladex every four weeks. Oral
antiandrogen casodex 50mg daily was given to ten patients on
zoladex depot, and four patients who had orchidectomy. Follow
up was effected monthly at which all patients were clinically re-
evaluated. All data were analysed and tabulated in various tables
as seen under the results.
RESULTS
The age range was 49 to 82 years with a mean of 65.1
± 2.0 years (Table 1). Digital rectal examination (DRE)
revealed hard or multinodular prostates with obliterated
median sulci and fixed rectal mucosae in all the 59
patients. Transrectal ultrasound of the prostate was
performed on 49 (83.05%) patients and revealed
extracapsular tumour in all these patients. Transperineal
trucut needle biopsy of the prostate was effected in all
patients under local anaesthesia and the histopathological
findings are illustrated in Table 2. Blood was taken for
serum prostate specific antigen (PSA) and was found to be
elevated above 20ng/ml in 92% of the 50 patients in which
it was measured Table 3. Plain x-rays of the pelvis and
lumbosacral spine showed evidence of osteosclerotic
metastases in 35 patients (59.32%) and osteolytic
metastases in three patients (5.08%). Distant metastasis in
the thoracic spine, the chest wall including the lungs was
present in five patients(8.47%).
Table 1
Age distribution in advanced prostate cancer
Age group in years No. of patients % of total
4-49 years 1 1.6
50-59 years 6 10.17
60-69 years 32 54.24
70-79 years 17 28.81
80-89 years 3 5.10
Total 59 100
Table 2
Histological degree of differentiation in advanced prostate cancer
Degree of differentiation Gleasons No. of % of total
(Gleasons grade) score patients
Grade 1 2 10 16.95
Grade 2 4 19 32.25
Grade 3 6 15 25.42
Grade 4 8 7 11.86
Grade 5 10 8 13.56
Table 3
Serum prostate specific antigen levels in advanced prostate cancer
Serum PSA level No. of patents % of total
0-4 ng/ml 1 2.0
5-10 ng/ml 1 2.0
11-20 ng/ml 2 4.0
Over 20 ng/ml 46 92.00
Table 4
Methods of treatment in advanced prostate cancer
Method of treatment No. of patients % of total
Total orchidectomy 2 3.39
Subcapsular orchidectomy 9 15.25
Oral diethylstilboestrol 8 13.56
3.6 mg zoladex depot monthly 23 38.98
3.6 mg zoladex depot and
          external radiotherapy 3 5.10
3.6 mg zoladex depot and
          oral casodex 50 mg daily 10 16.95
Orchidectomy and oral
          casodex 50 mg daily 4 6.78
Table 5
Survival of patients with advanced prostate cancer
Survival No. of No. of % alive of
patients dead patents alive Total
6 months 3 56 94.91
12 months 12 37 79.66
18 months 20 39 66.10
24 months 24 35 59.32
30 moths 29 30 50 85
36 months 31 28 47.46
42 months 35 24 40.68
48 months 37 22 37.29
Ureteric obstruction was observed in seven of the 40
patients (17.5%) who had intravenous urograms performed.
Six of the obstructions were unilateral with only one being
bilateral. The various methods of treatment effected for
patients are illustrated in Table 4. Survival of various
patients from 6-48 months is illustrated in Table 5.
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DISCUSSION
The rising incidence of and mortality from prostate
cancer has generated great interest in proving the results of
current methods available for treatment. Hormonal
manipulation in the treatment of advanced cancer was first
described by Higgins and Hodges in 1941(20) using
orchidectomy or oestrogen injections. Oestrogen inhibits
lutenizing hormone (LH) and follicular stimulating
hormone (FSH) secretion by the pituitary, in turn inhibiting
testosterone secretion by the testis. The most commonly
used oestrogen has been diethystilboestrol. The
administration of diethystilboestrol one milligramme three
times daily produces castrate levels of testosterone within
7-21 days (21). In this study, only eight patients (13.56%)
were treated with diethystilboestrol. This was because
these patients refused orchidectomy and could not afford
the high cost of lutenizing hormone releasing hormone
(LHRH) analogues. Stilboestrol is not the preferred
treatment of choice for advanced prostate cancer in this
locality because of the associated side effects which
include thrombosis, pulmonary embolism, myocardial
infarction, tenderness and enlargement of breasts, nausea,
vomiting and hot flushes. Parenteral administration of
oestrogens like diethylstilboestrol diphosphate
intravenously has however been shown to reduce
cardiovascular side effects(22).
In this study bilateral orchidectomy was performed on
15 patients (25.42%). Bilateral orchidectomy was considered
the gold standard as it caused a 95% reduction of the
circulating testosterone. However, this may not accurately
reflect the intraprostatic concentration of dihydrotestosterone
DHT originating from other estragonadal sources after
surgical castration, intraprostatic DHT remains at 40% of
measured levels in intact men (23). The importance of non
testicular sources, for example, the adrenal androgens in
adult men is the basis of adding antiandrogen therapy to
castration regardless of how it is achieved.
Lutenizing hormone releasing hormone LHRH is a
decapeptide. Substitutions at the sixth, ninth and tenth
positions results in the production of analogues with
greater than 100 times the potency of the naturally occurring
LHRH agonist, for example, goserelin (zoladex) interferes
with its pulsatile release from the hypothalamus and
desensitises the pituitary with subsequent suppression of
LH release. Suppression of LH release results in a decrease
in testosterone to castrate level (24,25). The majority of
patients in this study (61.01%), were treated with 3.6mg
subcutanous zoladex depot every four weeks. Side effects
of LHBH agonists include hot flushes and sexual
dysfunction, none of which was reported in this study.
Antiandrogens like bicalutamide (casodex) act
peripherally by blocking androgen uptake and/or nuclear
binding of testosterone at the target prostate cancer tissue.
In this study 10 patients were treated with oral casodex 50
mg daily in addition to the monthly 3.6 mg zoladex depot.
Another four patients who had bilateral orchidectomy were
treated with oral casodex 50 mg daily. More evidence is
now available to support the benefit of the combination of
an antiandrogen such as casodex with orchidectomy or
medical castration with LHBH agonists in patients with
advanced prostate cancer (26,27). Continuous double blind
trials with combination of antiandrogens and medical or
surgical castration have shown improvements in objective
response rates, progression free survival and overall survival
for maximum androgen blockade compared with castration
alone (28,29). The only significant limiting factor concerning
the use of combined androgenic blockade is the issue of
high cost to the patient. Perhaps one possibility that may
help address the economic concerns in future could be the
application of intermittent androgenic blockade which may
be expected to increasingly emerge as a potential treatment
if proved effective.
There are many unresolved issues in the diagnosis
and treatment of both early and advanced prostate cancer
(3,30). The clinical course of localised prostate cancer is
unpredictable while some patients die within one to two
years of diagnosis, others develop no symptoms during
their lifetime indicating a highly variable biological
potential for prostate cancer (31,32). In this study fifteen
(25.42%) patients had poorly differentiated and
undifferentiated cancers, Gleasons grades 4 and 5 on
histopathological examination. Fifteen patients (25.42%)
had moderately differentiated Gleasons grade 3 cancer
while another twenty patients (49.15%) had well
differentiated Gleasons grade 1 and 2 cancer (Table 2). All
the fifteen patients in this study with poorly differentiated
and undifferentiated cancers died within 12 months of
diagnosis irrespective of the mode of treatment (Tables 4
and 5). This is in conformity with the well known fact that
the prognosis in prostate cancer is dependent on both the
clinical stage of tumour according to the tumour node and
metastasis (TNM) classification(33) at the time of first
presentation, and the histopathological degree of
differentiation as determined by Gleasons grades(34).
Apart from Gleasons grades, many other tumour grading
systems have been proposed including the Mostofi
system(35), the Gaeta system(36), the Bocking system(37),
and the Anderson hospital system(38). Today, the Gleasons
grading system remains the most commonly utilised and
widely accepted. The Gleason system utilises glandular
configuration and the amount of tumour showing specific
histologic patterns to develop a scoring system (from 1-5)
that lends equal weight to the dominant and secondary
areas of the neoplasm (38). Furthermore, it is now believed
that most prostate cancers progress from small well
differentiated tumours to large poorly differentiated
tumours which disseminate with subsequent poor
prognosis(39). The rate of progression and probable clinical
outcome in any given case are reflected by the clinical
stage of tumour as determined by digital rectal examination,
histological grade and volume of tumour, and the serum
levels of prostate specific antigen (PSA) which has turned
out to be the most sensitive tumour marker in human
prostate cancer. PSA is widely used in early detection of
prostate cancer and in the follow up of patients after
radical prostatectomy in which its elevation indicates
residual disease and progression. Although poorly
differentiated prostate cancer tissue produces less PSA per
unit volume, this is thought to be compensated for by the
generally larger volume and greater cellularity of tumours
with high Gleasons grades(40,41). PSA however is not a
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useful marker for the presence or absence of metastatic
disease. The Veterans Administration Co-Operative
Urological Research Group, the National Prostate Cancer
Group, and the European Organisation for Research on
Treatment of Cancer Genitourinary G Group (EORTC-
GU) have all performed analyses to identify prognostic
variables in patients with advanced prostate cancer. They
reported the prognostic factors to include elevated serum
phosphates, upper urinary tract obstruction, tumour grade
and stage, the performance status, and other variables such
as serum PSA(42).
Most of patients who died had hormone resistant
tumours. The treatment objective in hormone resistant
prostate cancer should be palliation, particularly the relief
of pain especially in the bones during the usual average of
11-12 months survival from the time of diagnosis. Quality
rather than duration of life is the main objective in dealing
with this group of patients. Pain relief is often achieved by
radiotherapy which may be local wide field or systemic
with complete relief reported in upto 80% of the patients
thereby improving significantly their quality of   life(43,44).
Administration of chemotherapeutic agents may also be
considered in some cases although a significantly greater
toxicity and highly increased cost treatment should be
weighed against the potential clinical benefits before
reaching the decision.
Twenty patients (90.9%) of the 22 patients still surviving
at 48 months during the study had well differentiated
cancers with low Gleasons grades 1 and 2 which were all
hormone responsive, confirming good prognosis for these
group of tumours (Table 5) . The ideal of combined
androgen blockade using a non steroidal antiandrogen and
surgical or medical castration should be initiated as gold
standard therapy for patients with metastatic well
differentiated and moderately differentiated hormone
resposive prostate cancer. From this study it is concluded
that survival in the undifferentiated and poorly differentiated
prostate cancer Gleasons grades 4 and 5 with a score of over
7 is poor irrespective of mode of treatment.
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